Male Stress Urinary Incontinence
Male stress urinary incontinence (SUI) most commonly results from sphincteric insufficiency following radical prostatectomy, radiation therapy, TURP, or trauma to the external urethral sphincter. Treatment selection depends on incontinence severity (pad count, pad weight), prior radiation, urethral health, patient dexterity, and preference. Options range from conservative (pelvic floor rehabilitation, penile compression) to surgical (slings, adjustable devices, AUS).
Decision Framework
PFMT is the universally recommended first-line therapy for post-prostatectomy incontinence (PPI) across all major guidelines (EAU, AUA / SUFU, BAUS, ICI, CUA); network meta-analysis ranks electrical stimulation + biofeedback + PFMT highest for objective and patient-reported outcomes (Zhao 2025). Surgery should generally be deferred until ≥ 12 months post-prostatectomy to allow spontaneous recovery, with urodynamics and cystoscopy before any surgical intervention to confirm stress-only incontinence and exclude bladder-neck contracture or stricture.
The AUS (AMS-800) remains the gold standard for moderate-to-severe SUI (AUSCO 2025: 94% > 50% pad-weight reduction, 60% zero pad use at 12 months) — but reintervention-free survival is 71% / 57% / 40% at 2 / 5 / 10 years (Lenfant 2025, n = 8,475). The MASTER RCT (n = 380, Abrams 2021) established that the male transobturator sling is noninferior to AUS at 12 months for primary continence — making fixed slings (AdVance / AdVance XP) a reasonable first-line surgical option for mild-to-moderate non-radiated SUI. ATOMS has emerged as a versatile adjustable option and a proven second-line device after failed fixed slings (Queissert 2021). Prior radiation consistently predicts worse outcomes across all sling types and shifts the decision toward AUS. Unlike female SUI, urethral bulking agents have a very limited evidence base in men (Toia 2019: 8 studies, dry rates 0–83%) and are reserved for highly selected patients.
Treatment Selection by Clinical Scenario
| Clinical Scenario | First-Line Surgical Option | Alternative(s) | Avoid |
|---|---|---|---|
| Mild SUI (1–2 PPD), no prior radiation | Fixed sling — AdVance / AdVance XP | ATOMS (adjustable); ProACT | — |
| Moderate SUI (3–5 PPD), no prior radiation | AUS (AMS-800) preferred | ATOMS or AdVance XP (Sacco 2021: AUS 94.3% vs sling 68.6% at 12 mo) | Fixed sling alone in radiation history |
| Severe SUI (> 5 PPD) | AUS (AMS-800) | — | Fixed sling; bulking agents |
| Mild-moderate SUI, poor surgical candidate or declines implant | ProACT periurethral balloons (60% dry / 82% improved) | Urethral bulking (niche role; limited male data) | — |
| SUI with prior pelvic radiation | AUS (AMS-800) preferred | ATOMS (62.5% vs 87.9% non-radiated continence) | Fixed sling — radiation is a strong failure predictor |
| Recurrent SUI after failed fixed sling | ATOMS (Queissert 2021: 76.1% social continence at 42.5 mo after failed AdVance) | AUS (AMS-800) | Repeat fixed sling |
| Recurrent SUI after failed AUS | AUS revision / replacement; salvage with tandem cuff | Larger-cuff revision (urethral atrophy is the most common nonmechanical failure — 56.5% of revisions; Bentellis 2021) | — |
| Concomitant SUI + erectile dysfunction | Simultaneous AUS + penile prosthesis (synchronous or staged) | Sling + penile prosthesis | — |
| Mixed incontinence (SUI + urgency / OAB) | Optimize OAB component first via the OAB / UUI pathway (anticholinergic / β-3 / botulinum toxin / SNM) → reassess SUI | If pure SUI persists after OAB control → standard surgical pathway | — |
| Devastated outlet, all options exhausted | Bladder-neck closure + continent catheterizable channel | Urinary diversion | Continued failed reconstruction |
Sling / Adjustable Device Sub-Comparison
| Feature | Fixed Sling (AdVance XP) | Adjustable (ATOMS) | Adjustable (Argus) | ProACT Balloons |
|---|---|---|---|---|
| Mechanism | Sphincter repositioning | Cushion compression + adjustable | Suburethral compression + adjustable | Periurethral balloon compression |
| Best indication | Mild-moderate, non-radiated | Mild-moderate; second-line after failed sling | All severities | Mild-moderate, non-radiated |
| Dryness rate | ~60–84% | 68% (Angulo 2019 meta) / 80% (Doiron 2019) | 72% (Bochove-Overgaauw) | 60% (Larson 2019 meta) |
| Postop adjustability | No | Yes (scrotal port) | Yes (suprapubic regulator) | Yes (scrotal port) |
| Explant rate | Low | 5% | 55% (mostly Clavien I–II) | 24% |
| Prior-radiation tolerance | Poor | Reduced (62.5% vs 87.9%) | Limited data | Limited data |
| Use after failed sling | Not recommended | Yes — proven second-line | Limited data | Limited data |
AUS vs Sling Snapshot
- MASTER RCT (Abrams 2021, n = 380): male transobturator sling noninferior to AUS at 12 mo (87.0% vs 84.2% incontinence rates). Sling had fewer serious adverse events (6 vs 13).
- AUSCO trial (Kaufman 2025, n = 115, 17 sites): 94% > 50% pad-weight reduction, 60% zero pad use, 7.8% 12-month revision rate.
- Sacco 2021 propensity match (moderate PPI): AUS 94.3% vs fixed sling 68.6% continence at 12 mo — AUS clearly superior in moderate disease.
- Geretto 2023 propensity match (AUS vs ATOMS): AUS dryness 44.9% vs 22.5%, but more high-grade complications and reinterventions; 5-year device survival favors ATOMS (82% vs 67%).
- Lenfant 2025 national database (n = 8,475): AUS reintervention-free 71% / 57% / 40% at 2 / 5 / 10 yr — durability is the principal long-term concern.
Stepwise Escalation Ladder
- Conservative therapy — PFMT ± biofeedback ± electrical stimulation; lifestyle modifications; minimum 6–12 months
- Containment — penile clamp, condom catheter, pads (combination strategy preferred)
- Urethral bulking — niche role, mild SUI in poor surgical candidates
- Fixed male sling (AdVance / AdVance XP; Virtue) — mild-to-moderate SUI without radiation
- Periurethral balloons (ProACT) or adjustable sling (ATOMS, Argus, REMEEX) — alternative to fixed sling or as second-line after failed fixed sling
- AUS (AMS-800) — moderate-to-severe SUI, irradiated patients, or after failed sling
- AUS revision / tandem cuff — for failed AUS (urethral atrophy or mechanical failure)
- Bladder-neck closure / urinary diversion — last resort
For mixed incontinence with an OAB / urgency component, optimize the OAB pathway first (see OAB & UUI database — anticholinergics / β-3 / botulinum toxin / SNM) and then reassess SUI severity. Pharmacotherapy is not effective for pure male SUI and is not part of this ladder.
| Treatment | Category | Best for / indication |
|---|---|---|
| Pelvic Floor Muscle Training (PFMT) | Conservative | First-line for every PPI patient; perioperative through ≥ 6–12 months postop. |
| Biofeedback Therapy (BFT) | Conservative | Adjunct to PFMT in early postop period; patients unable to isolate the sphincter. |
| Pelvic Floor Electrical Stimulation | Conservative | Adjunct to PFMT + biofeedback in first 3 months post-prostatectomy. |
| Behavioral & Lifestyle Modifications | Conservative | Universal adjunct — fluid / caffeine / constipation / smoking modifications. |
| Weight Loss | Conservative | BMI ≥ 25 — ≥ 5% loss for clinically meaningful effect. |
| Penile Clamp (External Compression Device) | Conservative | Short vigorous activities (exercise, swim); intact cognition / sensation / dexterity required. |
| Condom Catheter (External Sheath) | Conservative | Extended activities, overnight, hospital fall-prevention; CIC alternative in selected SCI reflex-voiders. |
| Absorbent Pads | Conservative | Everyday / overnight wear, often combined with a clamp or sheath for activities. |
| Urethral Bulking Agents | Periurethral Bulking | Niche — mild SUI in poor surgical candidates declining more invasive options. |
| AdVance / AdVance XP Sling | Compressive Sling — Fixed | Mild-to-moderate SUI (≤ 3 PPD), no prior radiation; first-line surgical option. |
| Virtue Quadratic Sling | Compressive Sling — Fixed | Mild-to-moderate SUI; alternative to AdVance when fixation can be optimized. |
| ATOMS (Adjustable Transobturator Male System) | Compressive Sling — Adjustable | Mild-to-moderate SUI; proven second-line after failed AdVance; adjustability without re-operation. |
| Argus Sling (Classic / T) | Compressive Sling — Adjustable | Largely superseded by ATOMS; consider only at experienced high-volume centers. |
| REMEEX (Male Readjustable Sling, MRS) | Compressive Sling — Adjustable | Niche when truly non-invasive percutaneous re-tensioning is the priority. |
| ProACT Periurethral Balloons | Periurethral Balloon | Mild-to-moderate non-radiated SUI when patient declines an implant or is a poor surgical candidate. |
| Artificial Urinary Sphincter (AMS-800) | Sphincter | Moderate-to-severe SUI; prior radiation; failed sling; gold standard. |
| AUS Revision / Tandem Cuff | Sphincter | Recurrent SUI after functioning AUS — urethral atrophy or mechanical failure. |
| Bladder-Neck Closure + Catheterizable Channel | Salvage | Devastated outlet after failed AUS / sling; CIC-tolerant. |
| Urinary Diversion | Salvage | Last resort — intractable incontinence with non-functional outlet. |